Geneflux Biosciences is a multidimensional diagnostic company focussed towards providing specialized, high-end confirmatory & predictive tests to a robust customer base comprising of all major tertiary hospitals, medical centres and community health care providers in Malaysia. Established in the year 2007, Geneflux now has subsidiaries and branch offices in the UK (London), USA (Detroit) and India (Bangalore). Headquartered in Puchong, Selangor in our state of the art molecular diagnostic laboratory, Geneflux has been at the forefront of the fast-evolving diagnostic spectrum in Malaysia.
Geneflux® Biosciences is a privately held, research and technology driven Biotechnology Company specialized in the manufacture of molecular diagnostic kits and providing services to government and private hospitals in Malaysia. We are a “BioNexus Status” (2008) company.
Geneflux® was established in the year 2007 in Malaysia with registered offices in India, UK and USA.
We are focused on “polymerase chain reaction (PCR)” and “next generation sequencing” (NGS) technologies. Our flagship product, MyDENKit (Acronym for Malaysian Dengue Kit) received the decorated ‘Excellence award” from the Ministry of Science, Technology and Innovation (MOSTI) in 2009. We have got a very well equipped biotechnology laboratory, which has capability to manufacture hundred kits and analyze thousands of clinical specimens every day. We are also the recipient of Frost & Sullivan awards namely, “2010 Asia Pacific Niche Company of the Year Award in Molecular Diagnostics” and “2012 South East Asian Fastest Growing Company in Molecular Diagnostics for Infectious Diseases”. In 2013, the “Biotechnology Excellence Award” was given to Geneflux® by MOSTI, Malaysia and “Bio Medical Excellence Award 2013” from Biotech Corp.
Our Company is accredited with ISO 9001: 2008, ISO 13485: 2003 and ISO 17025: 2005. Our quality initiatives include engaging in IMR’s External Quality Assessment Scheme as well as enrollment into RCPA QAP, Australia which is a reputed international external quality assurance body. We have technology licenses for RT-PCR methods for Dengue virus detection and serotyping (2008 to 2018), MuRSAflux-MRSA detection (2008-2018) and MelioKit-detection of Melioidosis (2010-2020). In Malaysia, a team of 23 staff, who are passionate and focused on delivering quality test results to more than 80 customers, perform about 30 Infectious Diseases PCR tests and more than 40 different genetic mutation and drug efficacy tests.
Should you require any further clarification or information regarding our services, please do not hesitate to contact our Hotline number 03-8076 8154 or 03-8070 1154 or email: genefluxb[email protected]